Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Blepharitis. This also is a target of Brilacidin potentially, related to its eye use, recently discussed on the board. Another company I have followed, InSite Vision, did careful trials showing that the antibiotic component of treatment was not important compared to the inflammatory component. Specifically, adding Azithromycin to treatment was of no extra benefit to a steroid. The steroid was helpful, however. InSite Vision has done poorly, but the trials are helpful in suggesting the importance of inflammation in the problem.

Brilacidin has this antinflammatory activity, a bit hard for me to grasp, but I see the graphs for various immune modulators as just presented in Denmark, for example. And CTIX keeps stressing this aspect- with ulcerative colitis, esp, and mucositis.

There is no approved drug for blepharitis. InSite Vision estimated the market at $500 million. Blepharitis is a chronic disease of the elderly, for the most part. That number may or may not be correct, but this is another area Brilacidin might fit that is a bigger opportunity than one might suspect.